



Recent Advances in Lung Cancer

Guest Editor:

Dr. Bassam Redwan

Department of Thoracic Surgery,
Westfalen Hospital, 44536 Lünen,
Germany

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

Dear Colleagues,

Lung cancer represents the leading cause of death and the second most common cancer worldwide. The last decade has seen substantial development in the molecular and genetic diagnostics and therapy for this disease. This issue of the *International Journal of Molecular Sciences* aims to highlight new therapeutic agents, including modern antibody and immunotherapeutic agents. In addition to molecular pathways and related targeted therapy concepts—such as programmed death ligand-1 inhibition (PD-L1)—we will discuss common molecular mutations such as the EGFR gene, ALK rearrangements, and KRAS mutations, as well as less common molecular alterations in MET, HER2, BRAF, ROS1, RET, and NTRK. Moreover, we will address the roles of mutational analysis and next-generation sequencing (NGS) in the diagnosis of and therapy for lung cancer, especially in the differentiation between synchronous tumours and metastases.

Dr. Bassam Redwan

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI